These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28844952)

  • 1. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current controversies in cholangiocarcinoma.
    Hoyos S; Navas MC; Restrepo JC; Botero RC
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1461-1467. PubMed ID: 28756216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoresistance and chemosensitization in cholangiocarcinoma.
    Marin JJG; Lozano E; Herraez E; Asensio M; Di Giacomo S; Romero MR; Briz O; Serrano MA; Efferth T; Macias RIR
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1444-1453. PubMed ID: 28600147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.
    Macias RIR; Banales JM; Sangro B; Muntané J; Avila MA; Lozano E; Perugorria MJ; Padillo FJ; Bujanda L; Marin JJG
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1468-1477. PubMed ID: 28782657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
    Chung BK; Karlsen TH; Folseraas T
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.
    Cadamuro M; Stecca T; Brivio S; Mariotti V; Fiorotto R; Spirli C; Strazzabosco M; Fabris L
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1435-1443. PubMed ID: 28757170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholangiocarcinoma: State of the Art.
    Moazzami B; Majidzadeh-A K; Dooghaie-Moghadam A; Eslami P; Razavi-Khorasani N; Iravani S; Khoshdel A; Shahi F; Dashti H; Mehrvar A; Nassiri Toosi M
    J Gastrointest Cancer; 2020 Sep; 51(3):774-781. PubMed ID: 32157571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
    Gbolahan O; Hashemi-Sadraei N; O'Neil B
    J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK; Bridgewater J; Gores GJ; Zhu AX
    J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
    Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
    Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
    Ilyas SI; Gores GJ
    Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.